Lite Strategy Inc (LITS)

Lite Strategy Inc stock is traded at $1.03, with a volume of 63,245. It is up +5.44% in the last 24 hours and down -27.30% over the past month. Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.